RT Journal Article
SR Electronic
T1 Collateral damage: the impact on cancer outcomes of the COVID-19 pandemic
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.21.20073833
DO 10.1101/2020.04.21.20073833
A1 Amit Sud
A1 Michael Jones
A1 John Broggio
A1 Chey Loveday
A1 Bethany Torr
A1 Alice Garrett
A1 David L. Nicol
A1 Shaman Jhanji
A1 Stephen A. Boyce
A1 Phillip Ward
A1 Jonathan M. Handy
A1 Nadia Yousaf
A1 James Larkin
A1 Yae-Eun Suh
A1 Stephen Scott
A1 Paul D.P. Pharoah
A1 Charles Swanton
A1 Christopher Abbosh
A1 Matthew Williams
A1 Georgios Lyratzopoulos
A1 Richard Houlston
A1 Clare Turnbull
YR 2020
UL http://medrxiv.org/content/early/2020/04/29/2020.04.21.20073833.abstract
AB Background Cancer diagnostics and surgery have been disrupted by the response of healthcare services to the COVID-19 pandemic. Progression of cancers during delay will impact on patient long-term survival.Methods We generated per-day hazard ratios of cancer progression from observational studies and applied these to age-specific, stage-specific cancer survival for England 2013-2017. We modelled per-patient delay of three months and six months and periods of disruption of one year and two years. Using healthcare resource costing, we contextualise attributable lives saved and life years gained from cancer surgery to equivalent volumes of COVID-19 hospitalisations.Findings Per year, 94,912 resections for major cancers result in 80,406 long-term survivors and 1,717,051 life years gained. Per-patient delay of six months would cause attributable death of 10,555 of these individuals with loss of 205,024 life years. For cancer surgery, average life years gained (LYGs) per patient are 18·1 under standard conditions and 15·9 with a delay of six months (a loss of 2·3 LYG per patient). Taking into account units of healthcare resource (HCRU), surgery results on average per patient in 2·25 resource-adjusted life years gained (RALYGs) under standard conditions and 1·98 RALYGs following delay of six months. For 94,912 hospital COVID-19 admissions, there are 474,505 LYGs requiring of 1,097,937 HCRUs. Hospitalisation of community-acquired COVID-19 patients yields on average per patient 5·0 LYG and 0·43 RALYGs.Interpretation Delay of six months in surgery for incident cancers would mitigate 43% of life years gained by hospitalisation of an equivalent volume of admissions for community acquired COVID-19. This rises to 62% when considering resource-adjusted life-years gained. To avoid a downstream public health crisis of avoidable cancer deaths, cancer diagnostic and surgical pathways must be maintained at normal throughput, with rapid attention to any backlog already accrued.Funding Breast Cancer Now, Cancer Research UK, Bobby Moore Fund for Cancer Research, National Institute for Health Research (NIHR)Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by the Institute of Cancer Research. MEJ additionally received funding from Breast Cancer Now. GL is supported by a Cancer Research UK Advanced Clinician Scientist Fellowship Award [C18081/A18180] and is Associate Director of the multi-institutional CanTest Collaborative funded by Cancer Research UK [C8640/A23385]. B.T and A.G. are supported by Cancer Research UK award C61296/A27223. R.S.H. is supported by Cancer Research UK (C1298/A8362) and Bobby Moore Fund for Cancer Research UK). A.S. is in receipt of an Academic Clinical Lectureship from National Institute for Health Research (NIHR) and Biomedical Research Centre (BRC) post-doctoral support. The funding sources had no part in the study design, in the collection of data, in the analysis and interpretation of the data, in the writing of the report, or the decision to submit the manuscript. The corresponding author had full access to all the data in the study and had the final decision to submit the manuscript.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis work uses data that has been provided by patients and collected by the NHS as part of their care and support. The data are collated, maintained and quality assured by the National Cancer Registration and Analysis Service, which is part of Public Health England (PHE).